What type of medication is Roflumilast?

Roflumilast is classified as a phosphodiesterase-4 (PDE4) inhibitor. This type of medication works by inhibiting the enzyme phosphodiesterase-4, which leads to an increase in intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP levels result in anti-inflammatory effects within the airways, making Roflumilast particularly effective for managing chronic obstructive pulmonary disease (COPD). By reducing inflammation, it helps to improve lung function and reduce flare-ups in patients with this condition.

Roflumilast is not a leukotriene receptor antagonist, inhaled corticosteroid, or beta-agonist, which each serve different roles in the treatment of respiratory diseases. Leukotriene receptor antagonists target leukotriene pathways, inhaled corticosteroids reduce inflammation via corticosteroid mechanisms, and beta-agonists primarily serve to relax and open the airways. Therefore, recognizing Roflumilast as a PDE4 inhibitor accurately reflects its mechanism of action and therapeutic use.